Investigational drug · Phase 3
Socazolimab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cervical Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: May 14, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "Socazolimab"
First trial start
2024
Nov 28, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Socazolimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cervical Cancer
Approved drugs for the same conditions: Cervical cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Socazolimab" as an intervention, largest first.
- Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical CancerPivotal-lookingRecruiting
Lee's Pharmaceutical LimitedIndustry
NCT06459687 · 440 participants (planned) · Start Nov 28, 2024 · Primary completion Sep 1, 2027
Drug: Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab; Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab · For: Cervical Cancer
Sites: Hefei, China; Beijing, China; Wuhan, China · 5 sites in all
- A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.Status unknown
Lee's Pharmaceutical LimitedIndustry
NCT04460066 · 70 participants (planned) · Start Nov 18, 2020 · Primary completion Dec 6, 2021
Drug: anti-PD-L1 antibody; albumin bound paclitaxel and 2 more · For: Esophageal Cancer
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- First-line systemic treatment for people with extensive-stage small cell lung cancer: a network meta-analysis.
Ichimura T, Sugita H, Noma H, et al. · Cochrane Database Syst Rev 2026
- Cost-effectiveness of socazolimab plus chemotherapy vs. standard chemotherapy for first-line treatment of extensive-stage small cell lung cancer: a U.S. and China perspective.
Lang W, Wang J, Zhao H, et al. · Clin Transl Oncol 2026
- Socazolimab combined with carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis in China.
Tang L, Chen Y, Zhan S, et al. · PLoS One 2025
- Efficacy and safety of immunotherapy or antiangiogenic agent-based treatment strategies versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a network meta-analysis.
Wang C, Yang C, Zhao W, et al. · Front Pharmacol 2025
- Promising outcomes of the PD-L1 inhibitor Socazolimab in recurrent and metastatic cervical cancer: a case report.
Xu Z, Wang M, Gong L, et al. · Front Oncol 2025
- Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma.
Tang B, Xiao J, Chi Z, et al. · Oncologist 2025
Also in development for Cervical Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- SYS6002Phase 35 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Urothelial Carcinoma, Cervical Cancer, Advanced Solid Tumors
- JSKN033Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Cervical Cancer, Recurrent or Metastatic Cervical Cancer, Advanced Malignant Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.